Croci Do et al. showed that monoclonal anti-Gal-1 (F8.G7) (Table 2) based therapy inhibited tumor growth and angiogenesis, including pathways associated with VEGFR2/Gal-1 in mice with Kaposi’s sarcoma [44]. Here, KDR is linked to neoplasm.